Skip to main content
×
×
Home

Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials

  • Paola Bollini (a1), Sandro Pampaliona (a1), Giuseppe Tibaldi (a2), Bruce Kupelnick (a1) and Carmine Munizza (a3)...
Abstract
Background

Antidepressant drugs are usually prescribed at low doses, possibly to avoid adverse reactions. No comprehensive review has addressed the issue of dose, clinical response and tolerability in a quantitative way.

Aims

To determine whether high doses of antidepressants are more effective than lowdoses, and how safety is affected by dose.

Method

Trials comparing two or more doses of the same antidepressant were located, and all antidepressants administered were converted to the equivalent dose of imipramine. Generalised estimating equations were used to analyse percentage improvement and adverse event rate according to dose level.

Results

Thirty-three studies were identified. The dose level 100-200 mg imipramine equivalents showed an average improvement of 53% by ‘intention-to-treat’. Higher doses were not accompanied by increased efficacy, while lower doses showed reduction in efficacy. Adverse events significantly increased with dose.

Conclusions

With a low dose of antidepressants, clinicians trade off a slightly reduced chance of improvement for a higher chance of avoiding adverse reactions.

Copyright
Corresponding author
Dr Carmine Munizza, Centro Studi e Ricerche in Psichiatria, Piazza del Donatore di Sangue, 3, 10154 Torino, Italy
Footnotes
Hide All

Declaration of interest

Supported by the Centro Studi Richerche in Psichiatria (Turin, Italy), and by Angelini, Eli Lilli, Lundbeck, Ravizza. Roerig, Smith Kline Beecham and Solvay Pharma.

Footnotes
References
Hide All
Altamura, A. C., Montgomery, S. A. & Werniclce, J. F. (1998) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry. 153 (suppl. 3), 109112.
American Psychiatric Association (1976) Diagnostic and Statistical Manual of Mental Disorders (2nd edn) (DSM–II). Washington, DC: APA.
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington. DC: APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington. DC: APA.
Anderson, I. M. & Tomeson, B. M. (1995) Treatment discontinuation with selective serotonin re-uptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal, 310, 14331437.
Barnes, R. J. & Guarino, R. A. (1980) Single- versus multiple-dose comparative trial of desipramine hydrochloride: a double-placebo method. Journal of Clinical Pharmacology, 20, 681688.
Beasley, C. M. Jr., Sayler, M. E., Weiss, A. M., et al (1992) Fluaxetine: activating and sedating effects at multiple fixed doses. Journal of Clinical Psychophormocology, 12, 328333.
Benkert, O., Szegedi, A. & Wetzel, H. (1996) Minimum effective dose for antidepressants – an obligatory requirement for antidepressant drug evaluation? International Clinical Psychopharmacology, 11, 177185.
Bjerkenstedt, L., Edman, G., Fiyckt, L., et al (1985) Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor – a dose–response study in depressed patients. Psychopharmacology, 87, 253259.
Blashki, T. G., Mowbray, R. & Davies, B. (1971) Controlled trial of amitriptyline in general practice. British Medical Journal, i, 133138.
Branconnier, R. L., Cole, J. O., Ghazvinian, S., et al (1983) Clinical pharmacology of bupropion and imipramine in elderly depressives. Journal of Clinical Psychiatry, 44, 130133.
Brugha, T. S., Bebbington, P. F., Maccarthy, B., et al (1992) Antidepressants may not assist recovery in practice: a naturalistic prospective survey. Acta Psychiatrica Scandinavica, 86, 511.
Craig Nelson, J. (1997) Safety and tolerability of the new antidepressants. Journal of Clinical Psychiatry, 58, 2631.
D'Amico, M. F., Roberts, D. L., Robinson, D. S., et al (1990) Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacology Bulletin, 26, 147150.
Diggel, P., Liang, K. Y. & Zeger, S. L. (1994) Analysis of Longitudinal Data. New York: Oxford University Press.
Donoghue, J. M. & Tylee, A. (1996) The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. British Journal of Psychiatry, 168, 164168.
Dunlop, S., Dornseif, B., Wernicke, J. F. (1990) Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology Bulletin, 26, 173180.
Dunner, D. L. & Dunbar, G. C. (1992) Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53, 2126.
Fabre, L. F. & Putman, H. P. (1987) A fixed-dose trial of fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry, 48, 406408.
Fawcett, J. & Barkin, R. L. (1997) Efficacy issues with antidepressants. Journal of Clinical Psychiatry, 58 (suppl. 6), 3239.
Gram, L. F. (1990) Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clinical Neuropharmacology, 13 (suppl. I). S35S44.
Greenberg, R. P. & Fisher, S. (1989) Examining antidepressant effectiveness: findings, ambiguities, and some vexing puzzles. In The Limits of Biological Treatments for Psychological Distress. Comparisons with Psychotherapy and Placebo (eds Fisher, S. & Greenberg, R. P.), pp. 138. Hillsdale, NJ: Lawrence Erlbaum.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health.
Halaris, A. E., Stern, W. C., van Wyck Fleet, J., et al (1983) Evaluation of the safety and efficacy of bupropion in depression. Journal of Clinical Psychiatry, 44, 101103.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Hebenstreit, G. F., Felklerer, K., Zochling, R., et al (1989) A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatrica Scandinavica, 80 (suppl. 350). 8184.
Hotopf, M., Hardy, R. & Lewis, G. (1997a) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry, 170, 120127.
Hotopf, M., Lewis, G. & Normand, C. (1997b) Putting trials on trial – the costs and consequences of small trials in depression: a systematic review of methodology. Journal of Epidemiology and Community Health, 51, 354358.
Jadad, A., Moore, R. A., Carroll, D., et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials, 17, 112.
Katon, W., von Korff, M., Lin, E., et al (1992) Adequacy and duration of antidepressant treatment in primary care. Medical Care, 30, 6776.
Kendrick, T. (1996) Prescribing antidepressants in general practice (and subsequent letters). British Medical Journal. 313, 829830; 314, 826–829.
Khan, A., Fabre, L. F. & Rudolph, R. (1991) Venlafaxine in depressed outpatients. Psychopharmacology Bulletin, 27, 141144.
Martin, R. M., Hilton, S. R., Kelly, S. M., et al (1997) General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. British Medical Journal, 314, 646651.
Moncrieff, J., Wessely, S. & Hardy, R. (1998) Metaanalysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry, 172, 227231.
Montgomery, S. A., Rasmussen, J. G., Lyby, K., et al (1992) Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. International Clinical Psychopharmacology, 6 (suppl. 5), 6570.
Munizza, C., Tibaldi, F., Bollini, P., et al (1995) Prescription pattern of antidepressants in out-patient psychiatric practice. Psychological Medicine, 25, 771778.
Preskorn, S. H. (1994) Antidepressant drug selection: criteria and options. Journal of Clinical Psychiatry, 55 (suppl. A), 624.
Schiwy, W., Heath, W. R. & Delini-Stuia, A. (1909) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients. Journal of Neural Transmission. 28, 3344.
Spitzer, R. L., Endicott, J. & Robins, E. (1978) Research Diagnostic Criteria: rationale and reliability. Archives of General Psychiatry. 35, 773782.
Wernicke, J. F., Bosomworth, J. C. & Ashbrook, E. (1909) Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. International Clinical Psychopharmacology, 4, 6367.
Wilcox, C. S., Ferguson, J. M., Dale, J. L., et al (1996) A double-blind trial of low-and high-dose ranges of gepiron-ER compared with placebo in treatment of depressed patients. Psychopharmacology Bulletin, 32, 335341.
World Health Organization (1978) Mental Disorders: Glossary and Guide to their Classification in Accordance with the Ninth Revision of the International Classification of Diseases (ICD–9). Geneva: WHO.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials

  • Paola Bollini (a1), Sandro Pampaliona (a1), Giuseppe Tibaldi (a2), Bruce Kupelnick (a1) and Carmine Munizza (a3)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *